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Abstract 
Molecular classifications defining new tumor subtypes has been recently refined using 
genetic and transcriptomic analyses of benign and malignant hepatocellular tumors. Here, 
we performed microRNA (miRNA) profiling in two series of fully annotated liver tumors to 
uncover associations between oncogene/tumors suppressors’ mutations, clinical and 
pathological features. Expression levels of 250 miRNAs in 46 benign and malignant 
hepatocellular tumors were compared to 4 normal liver samples using quantitative RT-PCR. 
miRNAs associated to genetic and clinical characteristics were validated in a second series 
of 43 liver tumor and 16 non-tumor samples. miRNAs profiling unsupervised analysis 
classified samples in unique clusters characterized by histological features (tumor/non-tumor 
P<0.001; benign/malignant tumors P<0.01, inflammatory adenoma and focal nodular 
hyperplasia P<0.01), clinical characteristics (HBV infection P<0.001; Alcohol consumption 
P<0.05) and oncogene/tumor suppressor gene mutations (ß-catenin P<0.01; HNF1α 
P<0.01). Our study identified and validated miR-224 over-expression in all tumors, miR-200c, 
miR-200, mir-21, miR-224, miR-10b and miR-222 specific deregulation in benign or 
malignant tumors. Moreover miR-96 was over-expressed in HBV tumors, miR-126* down 
regulated in alcohol related HCC. Down-regulations of miR-107 and miR-375 were 
specifically associated with HNF1α and ß-catenin gene mutations, respectively. miR-375 
expression was highly correlated to that of ß-catenin targeted genes as miR-107 expression 
was correlated to that of HNF1α in a siRNA cell line model. Thus, it strongly suggests that ß-
catenin and HNF1α could regulate miR-375 and miR-107 expression levels, respectively. 
Conclusion: Hepatocellular tumors may have distinct miRNAs expression fingerprint 
according to malignancy, risk factors and oncogene/tumor suppressor gene alterations. 
Dissecting these relationships provides new hypothesis to understand the functional impact 
of miRNAs deregulation in liver tumorigenesis and their promising use as diagnostic markers. 
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Introduction 
Hepatocellular adenomas (HCA) and hepatocellular carcinomas (HCC) are liver tumors 
heterogeneous in nature with various risk factors, genetics alterations, and clinical features 
(1-3). HCA are rare benign liver tumors usually developed in women after an oral 
contraceptive use (4). They are sometime difficult to discriminate from well-differentiated 
HCC or from focal nodular hyperplasia (FNH), a benign regenerative lesion. Recently, we 
defined a new molecular classification of HCA according to genetic (HNF1α or ß-catenin 
mutations) and phenotypic (inflammation) features (5, 6). We showed that ß-catenin 
activated HCA were more at risk of malignant transformation than the other HCA subtypes. 
Hepatocellular carcinoma (HCC) is the most common malignant tumor in the liver and the 
third cause of death from cancer. Viral (HBV and HCV infection) and non-viral (Alcohol and 
aflatoxin B1 ingestion) agents are known to be associated to HCC occurrence. In each 
tumor, several oncogenic pathways are deregulated (2) and different subtypes of tumors are 
defined according to genetic and transcriptomic based classification (7, 8). Briefly, two main 
tumor groups related to chromosome stability/instability were identified and six subgroups 
(called G1 to G6) were found closely related to genetic (TP53 and ß-catenin mutations), 
activation of oncogenic pathways (AKT and IGF activation), clinical features (local invasion), 
and risk factors (HBV exposure).  
Apart of genetic and epigenetic abnormalities modifying oncogene and tumor suppressor 
genes, deregulation of microRNAs (miRNAs) may also contribute to carcinogenesis. miRNAs 
are small endogenous non-coding RNAs (~22 nucleotides) responsible for a post-
transcriptional expression regulation of targeted genes. They promote mRNA degradation 
and repress mRNA translation by sequence-specific interaction with the 3’-untranslated 
region of targeted mRNAs (9). Physiologically, miRNAs have been shown to be involved in 
several processes such as development, apoptosis, proliferation and differentiation (10, 11). 
Moreover their levels of expression are deregulated in a large number of tumors, some of 
them were found directly implicated in carcinogenetic mechanisms and several altered 
expression of miRNAs has previously been described in rat and human HCC (12-14).  
We hypothesized that miRNAs deregulation could be related to specific sub-groups of 
hepatocellular tumors defined by either oncogene/tumors suppressor mutations, histological 
or clinical features. We first analyzed the expression of 250 miRNAs in a series of 46 
malignant and benign hepatocellular tumors extensively characterized compared to 4 normal 
liver tissues. According to tumor classification, the most significant deregulated miRNAs were 
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selected and their differential expression was validated in a second series of 43 tumors and 
16 non-tumor liver tissues including cirrhosis and chronic hepatitis of various etiologies.  
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Patients and Methods 
Liver Samples and Clinical Data 
A whole series of 109 liver samples (55 HCC, 29 HCA, 5 Focal Nodular Hyperplasia, 
30 non tumor liver samples) were collected from 93 patients surgically treated in Bordeaux 
from 1992 to 2004. Liver tissues were immediately frozen in liquid nitrogen and stored at -
80°C until used for molecular studies. All the patients were recruited in accordance with 
French law and institutional ethical guidelines. Liver samples were fully clinically, 
histologically and genetically characterized and divided in two sets (Table 1). Hepatocellular 
adenomas (HCA) were classified according to the patho-molecular classification taking into 
account the HNF1α or ß-catenin mutations and the presence of inflammatory infiltrates (5, 6). 
HCC were classified according to the clinical, pathological and genetic features as 
classification previously described (7).  
Samples total RNAs extraction 
Total RNAs extraction was performed using TRIZOL® Reagent (Invitrogen). A 2 mm3 
frozen tissue sample was homogeneized in 800µl of TRIZOL® Reagent using a Tissue Lyser 
Mixer Mill MM 300 (Quiagen). The extraction was performed according to Invitrogen protocol. 
RNAs were quantified using NanoDrop® ND-1000 and quality was tested by migration of 200 
ng RNA on 0.8% agarose gel.  
Quantitative RT-PCR 
miRNAs quantitative RT-PCR was performed using TaqMan® MicroRNA Human 
Assays and the ABI PRISM® 7900HT System (Applied Biosystems). The first set of sample 
was analysed using a set of 250 miRNAs (Applied Biosystems, Supplementary Table 1). The 
expression of 22 miRNAs was further analysed in the validation set of tumors. For each 
sample and each miRNA tested, an independent retrotranscription using a specific reverse 
transcription primer was performed on 5 ng of totals RNAs according to manufacturer’s 
protocol. Ribosomal 18s (R18S) was used for the normalization of expression data. The 
relative amount of miRNAs and all mRNAs studied in samples, was determined using the 2-
 ✁  CT
 method where ✂✄✂ CT = (CTtarget-CTR18S)sample - (CTtarget-CTR18S)calibrator. Briefly, for the first 
set of samples, expression of a miRNA was normalized with R18S and with the mean 
expression of the corresponding miRNAs in the 4 normal liver samples. For the validation set 
of samples, expression was normalized with R18s and with one normal liver sample. As the 
same normal liver RNA was previously included in the first set of experiment, we verified the 
reproducibility of miRNA expression values obtained in the two experiments. Results of the 
validated miRNA are provided in Supplementary Table 2. 
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HNF1α/TCF1, GLUL, LGR5, TBX3 and PANK1 mRNA expression were measured as 
previously described (15) using pre-designed primers and probe sets from Applied 
Biosystems (probe set numbers: Hs00167041_m1, Hs00374213_m1, Hs00374213_m1, 
Hs00255591_m1, Hs00379740_m1). 
Clustering analysis 
In the first set of 50 samples, quantitative RT-PCR expression results for the 250 
tested miRNAs were filtered, 130 miRNAs were selected on the basis of a Ct value below 31 
in at least 10% of the tested samples (Supplementary Table 1). These 130 selected miRNA 
were used for an unsupervised clustering analysis. Dendrograms classifying samples and 
genes, with average linkage methods using Pearson correlation as a distance metric, was 
obtained based on the expression profile of quantitative RT-PCR using the dChip 2006 
software (http://biosun1.harvard.edu/complab/dchip/). Clusters were considered significantly 
associated with a feature when the P value was less than 0.05 with Pearson correlation. 
miRNAs significantly differentially expressed according to clinical or genetic features 
identified in the unsupervised clustering analysis were selected for supervised analyses 
(Supplementary Table 3).  
Statistical Analysis 
Statistical analysis was performed using dChip and GraphPad Prism softwares. 
Quantitative RT-PCR datas were first analysed for differences of expression between 
samples subgroups using dChip t-test and the nonparametric Mann-Whitney test. miRNAs 
with a fold change superior to 3 and statistically significant in the two test were selected for 
validation (Supplementary Table 4). All miRNAs expression data were presented as mean ± 
SEM in subgroups of tumors. Non-parametric Spearman test was used to compare 
quantitative values of expression. All reported P values were two-tailed and differences were 
considered significant when the P value was under 0.05. 
Cell Culture and Transfections 
HepG2 cells were cultured in Dulbecco’s modified Eagle Medium High Glucose 
(Invitrogen) supplemented with 10% fetal bovine serum, and penicillin/streptomycin. Cells 
were transfected using Lipofectamine RNAiMax (Invitrogen), in six wells plates, according to 
the manufacturer’s protocol. HNF1α extinction was performed with a siRNA targeting exon 8 
and 9 of HNF1α (siRNA 3544, sens :GGUCUUCACCUCAGACACUtt ; antisens : 
AGUGUCUGAGGUGAAGACCtg, Ambion). Several siRNA concentrations were tested (0, 
0.01, 0.05, 0.1, 0.2, 0.4, 0.6, 0.8, 1, 5, 10, 50 nM) in order to modulate the HNF1α 
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 
expression. Maximal inhibition of HNF1α 
 
protein was observed 72h post transfection (see 
Supplementary Fig. 1). BLOCK-iT Alexa Fluor Red Fluorescent Oligo (Invitrogen) was used 
as transfected dsRNA control. Western blot was performed using HNF1α antibody sc-6548 
(Santa Cruz Biotechnology). At this time, cells were lysed in TRIZOL® Reagent (Invitrogen) 
for RNA extraction.  
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Results 
 
Global profiling of miRNAs is related to well defined-subgroups of hepatocellular 
tumors  
We analyzed the expression level of 250 miRNAs in the first set of samples that included 28 
HCC, 13 HCA and 5 FNH compared to 4 normal liver tissues. An unsupervised analysis was 
performed after selection of the 130 miRNAs expressed in at least 10% of the samples (Fig. 
1A). It showed a significant partition between non-tumor and tumor samples (P<0.01), benign 
tumors were divided in three clusters significantly parted from HCC (P<0.01). Adenomas 
were grouped in two distinct clusters corresponding to HNF1α mutated (P<0.01) and 
Inflammatory HCA (P<0.01) respectively. Focal Nodular Hyperplasias were located on a third 
cluster (P<0.01) distinct from HCA. In contrast, ß-catenin mutated HCA were spread between 
two HCA clusters. HCC samples were partitioned in three different clusters significantly 
characterized either by a specific clinical risk factor (HBV, P<0.001; Alcohol intake, P<0.05) 
or by a gene mutation (ß-catenin, P<0.01). Two supervised analyses were performed to 
classify separately benign and malignant tumors using the list of genes differentially 
expressed in each clinical or genetic features significantly associated to clusters in the 
unsupervised analysis (Fig. 1B and C, Supplementary Table 3).  
Specific miRNA deregulations related to benign or malignant features.   
As shown above, miRNA profiling could classify hepatocellular tumors according to 
pathological, clinical and genetic features. Thus, we aimed to identify and validate, in a 
second series of tumors, miRNA with a deregulated expression the most closely associated 
to such specific features. First, we identified miRNAs specifically deregulated in tumors when 
compared with non-tumor liver samples, and several were validated (Fig. 2). Three miRNAs 
were found significantly up-regulated (miR-224) or down-regulated (miR-422b and mir-122a) 
in both benign and malignant tumors (Fig. 2A). Second, we validated miRNAs with a level of 
expression significantly different between malignant and benign tumors. Corresponding to 
these criteria, miR-200c and miR-203 were under-expressed in benign tumors (Fig. 2B) while 
mir-21, miR-222 and miR-10b were significantly over-expressed in HCC (Fig. 2C). Finally, 
miR-224, that was differentially expressed between tumor and non-tumor liver tissues, was 
also significantly over-expressed in HCC when compared to benign tumors (Fig. 2A).  
 
miRNAs deregulation related to tumor suppressor/oncogene mutations in HCA 
We searched for miRNAs deregulation that could characterize specific subgroups of benign 
tumors. While unsupervised clustering enabled to correctly classify inflammatory HCA and 
FNH in two specific clusters, no miRNA displayed a sufficient fold change of expression to 
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grant further validation. In contrast, a robust under expression of miR-375 was validated in ß-
catenin–mutated HCA when compared to the other HCA (fold change: -14.2, P<0.001 in 
overall samples, Fig. 3A). Among 15 miRNAs significantly deregulated in HNF1α-mutated 
HCA, we validated the under expression of miR-107 in HNF1α mutated HCAs when 
compared to the other HCA (fold change: -3.6; P<0.001, in overall samples, Fig. 3B). This 
observation suggested that the HNF1α transcription factor could regulate, directly or not, the 
expression of miR-107. To test this hypothesis, we performed an HNF1α silencing using 
several doses of specific siRNA targeting HNF1α in HepG2 hepatocellular cell line and we 
assayed the consequences on miR-107 expression level. The silencing of HNF1α 
significantly correlated with the extinction of miR-107 in a dose-effect manner (Spearman r: -
0.92; P<0.0001, Fig. 3C).This result suggested that HNF1α may control the expression of 
miR-107. MiR-107 is located in the intron 5 of PANK1 gene coding for the pantothenate 
kinase 1. We tested if the miR-107 and PANK1 expression could be co-regulated. We 
showed that PANK1 mRNA expression was not affected by HNF1α silencing, suggesting that 
regulation of miR-107 by HNF1α was independent of PANK1 status (Supplementary Fig. 2). 
According to the hypothesis of a direct regulation of miR-107 by HNF1α, the in silico search 
(using Genomatix softwares) revealed two potential HNF1α binding sites located -1852 and -
1543 base pairs upstream of the pre-miRNA initiation site. However, the direct role of HNF1α 
remained to be fully demonstrated by a functional analysis of the putative promoter region. 
 
miRNAs deregulation related to genetic features and risk factors in HCC 
As shown in Fig. 1, miRNAs deregulations were associated with alcohol consumption and 
HBV infection in HCC. We validated miR-126* under-expression in HCC related to alcohol 
abuse when compared to the other HCC (fold change: 2.7; P<0.001, in overall samples, Fig. 
4A). Similarly, we also validated a significant over-expression of miR-96 in HBV related HCC 
when compared to non-infected tumors (fold change: 5.7; P<0.01, in overall samples, Fig. 
4B). In contrast, the level of expression of miR-126* and miR-96 did not vary significantly 
among the various subtypes of non-tumor liver tissues (Supplementary Fig. 3). In particular, 
no significant variation was observed in cirrhosis or in HBV related non-tumor samples. As 
suggested by the unsupervised clustering, no miRNA were found significantly deregulated in 
HCCs HCV infected versus non-infected HCCs. Similarly, no significant difference was found 
according to the level of cell differentiation. 
microRNAs deregulations were also related to the ß-catenin oncogene mutation in the 
unsupervised clustering analysis (Fig 1). As in ß-catenin mutated HCAs, we validated the 
extinction of miR-375 in HCC characterized by a ß-catenin activating mutation (fold change: -
44; P<0.001, in overall samples, Fig. 4C). We also found a significant anti-correlation 
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between the level of expression of miR-375 and three genes regulated by ß-catenin, TBX3, 
LGR5 and GLUL in HCA as well in HCC (Fig. 4D). Finally, no significant differences in 
miRNA expression was observed in non-tumor liver tissues according to HCV or HBV 
infection, alcohol intake and cirrhosis.  
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Discussion 
Aberrant patterns of miRNAs expression have already been described in several 
hematological and solid tumors, including HCC (see for review (16)). In the present work, we 
have identified, for the first time, miRNAs expression patterns that can unambiguously 
differentiate benign, malignant and several subtypes of hepatocellular tumors according to 
specific risk factors, oncogene and tumor suppressor gene mutations. These new findings 
and the most significant deregulated miRNAs are summarized in Fig. 5. 
In the present work, several miRNAs previously associated with malignancy were 
identified as significantly deregulated in hepatocellular subgroup of tumors. Most notably, we 
showed that miR-224 previously identified as over-expressed in HCC (14) was also up-
regulated in benign hepatocellular tumors, including adenomas and focal nodular hyperplasia 
that are regenerative polyclonal nodules (17), but at a lesser degree. Similarly, miR-122a has 
been previously found down-regulated in human and rodent HCC (12); this microRNA, highly 
expressed in the liver, is essential for HCV replication (18) and it modulates cyclin G1 
expression in HCC cell-line (19). Here, we showed that miR-122a is also down-regulated in 
both human benign and malignant hepatocellular tumors. Thus, concomitant analysis of 
benign and malignant tumors enabled us to associate deregulation of expression of miR-224, 
422b and 122a with common early events in hepatocellular tumorigenesis.  
Only few miRNAs deregulations have been previously described in benign tumors (20, 
21). Interestingly, in pituitary adenoma, miRNAs pattern of expression were significantly 
related to tumor subtype according to histotypes and secreting characteristics (20). In thyroid 
nodules, most of the miRNAs deregulated in carcinomas have demonstrated also an altered 
expression in adenomas (21). Here, we identified miRNA (miR-200c and miR-203) with an 
expression specifically down-deregulated in benign hepatocellular tumors when compared to 
normal liver tissues or HCC. A lower expression of miR-203 was also previously described in 
non-secreting pituitary adenomas when compared with growth hormone pituitary secreting 
adenomas (20). In hepatocellular tumors, we showed that miRNAs profile of expression in 
benign tumor differed according to tumor subtype defined by oncogene and tumor 
suppressor gene mutation or by histological phenotype. These results enlightened the 
importance of refining classification based on molecular and meticulous characterization of 
the tumor phenotypes, including for benign tumors.  
Here we validated a significant over-expression of miR-10b, miR-21 and miR-222 in HCC 
when compared with benign tumors and non-tumor liver tissues. Interestingly, over-
expression of these three miRNAs was previously identified as important key factors to 
promote cell invasion or proliferation in various epithelial tumor types. Recently, Ma and 
collaborators identified miR-10b as a microRNA highly expressed in metastatic breast tumors 
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that promotes cell migration and invasion (22). They showed that miR-10b expression is 
induced by twist allowing miR-10b to inhibit translation of the messenger RNA encoding 
homeobox D10, resulting in increased expression of a well-characterized pro-metastatic 
gene, RHOC. miR-222 over expression promotes cell proliferation by targeting p27Kip1 in 
prostate and thyroid carcinoma (23, 24). Finally, miR-21 over-expression down-regulates the 
Pdcd4 tumor suppressor and stimulates invasion, intravasation and metastasis in colorectal 
cancer (25). Higher over-expression of miR-21 was also previously associated with poorly 
differentiated HCC and it participates to down-regulate the level of expression of PTEN (13).  
Our results identified the deregulation of two miRNAs, miR-96 and miR-126*, as 
significantly associated with different risk factors of HCC, HBV infection and alcohol 
consumption, respectively. To our knowledge, miR-96 and miR-126* have not been directly 
implicated in pathways related to carcinogenesis. Because no significant variation in the 
expression of these two microRNAs was observed in non-tumor tissues according to HBV 
infection or alcohol intake, it suggests that microRNAs deregulations are directly linked to 
carcinogenetic processes specifically induced by these two risk factors. In fact, using 
transcriptomic and genetic global analyses we have previously shown that carcinogenesis 
mechanisms in HBV related HCC were particular, closely related to chromosome instability, 
AKT activation and fetal features in gene expression (7, 8). In contrast, microRNA profiling is 
the first global genomic approach that enabled to discriminate HCC related to alcohol abuse 
from the other tumors. Consequences of the miR-126* deregulation remained to be explored 
in alcohol related tumors and HCC associated to other risk factors.  
For the first time, we identified miRNAs deregulation in hepatocellular human tumors 
closely related to specific oncogene or tumor suppressor gene mutations. However, in cell 
line models, some miRNAs have been shown to be under control of oncogene (27) or tumor 
suppressor (28). The low expression of miR-375 in both HCA and HCC mutated for ß-catenin 
together with the highly significant anti-correlation between miR-375 level of expression and 
genes targeted by ß-catenin argue for a direct link between β-catenin activation and 
repression of miR-375. This is an important result since ß-catenin is a major oncogene 
activated in 30 to 40% of the HCC. It increases the complexity of regulation of expression by 
ß-catenin adding yet another layer of control with microRNA to the RNA and translation 
control level. In HCA, we showed a specific under-expression of miR-107 in HNF1α 
inactivated samples. It has been suggested by in silico analysis that miR-107 could regulate 
the expression level of several predicted target proteins involved in lipid metabolism. Under-
expression of miR-107 is predicted to promote acetyl-coA and lipids levels (26). Interestingly, 
we previously showed that HNF1α inactivated HCA exhibited a steatotic phenotype resulting 
from an activation of lipogenesis (29). Thus, we can hypothesize that miR-107 under-
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expression specifically observed in HNF1α inactivated HCA may contribute to the steatotic 
phenotype and lipid accumulation. Our data suggest that this miRNA could be regulated by 
HNF1α like the recently identified miR-194 during intestinal epithelial Caco-2 cell line 
differentiation (30).  
In conclusion, this work revealed an additional layer of gene alterations to better 
characterize hepatocellular tumors. It allowed the identification of miRNAs deregulation 
closely correlated to clinical and histological subtypes of tumors as well as to oncogene and 
tumor suppressor gene mutations. The gene and protein networks directly targeted and 
affected by these miRNAs that participate to tumorigenesis remain to be extensively 
explored. 
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Fig. 1. (A) Unsupervised hierarchical clustering of miRNA profiling in 50 liver samples. The 
dendrogram in the upper panel was obtained on the basis of the quantitative RT-PCR data of 
the 130 miRNAs expressed in at least 10% of the liver samples that included 4 normal livers, 
28 HCC, 13 HCA and 5 FNH. (B) Supervised clustering analysis of miRNA significantly 
expressed according to each sub-group (see Supplementary Table 3) in the 18 benign 
tumors samples. (C) Supervised clustering analysis of miRNA differentially expressed in β-
catenin mutated HCC, alcohol related HCC and HBV infected HCC (see Supplementary 
Table 3) in the 28 HCC samples. The different significant tumors subgroups are indicated in 
color. The heat map, in the lower panel, shows the expression of miRNAs across samples. 
For each miRNA probeset, data are median-centered (black), with the lowest and highest 
intensity values in green and red, respectively. 
Fig. 2. miRNAs the most significantly deregulated in hepatocellular tumors. (A) miR-224 was 
found over-expressed, miR-422b and miR-122a were found down regulated in tumors when 
compared to non tumor liver. (B) miR-200c and 203 were found under-expressed in benign 
tumors when compared to HCC. (C) miR-21, 222 and 10b were found over-expressed in 
HCC when compared to benign tumors. FS=First Set of tumors, VS=Validation Set of 
tumors. B=Benign tumors (FS n=18; VS n=12); HCC=Hepatocellular Carcinomas (FS n=28; 
VS n=22); NL=Normal Livers (n=4), NTL=Non Tumor Liver (n=16, including cirrhosis n=9; 
HBV infected n=6; HCV infected samples n=5; alcohol liver disease n=5). Data are presented 
as the mean fold compared to the mean value in non tumor samples ± SEM. Statistical 
analysis was performed using Mann-Whitney test, *P<0.05; **P<0.01; ***P<0.001.  
 
Fig. 3. miRNAs deregulation associated to tumor suppressor gene or oncogene mutation in 
HCA. (A) miR-375 was under-expressed in β-catenin mutated HCA (β-c Mut; FS n=5, VS 
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n=4), versus non mutated HCA (β-c Wt; FS n=13, VS n=8). (B) miR-107 was found down-
expressed in HNF1α mutated HCA (Hα Mut; FS n=4; VS n=7), versus non mutated HCA (Hα 
Wt; FS n=9, VS n=8). For Normal Liver (NL) and Non Tumor Liver (NTL) distribution, see Fig. 
2. (C) Correlation between miR-107 and HNF1α transcript level of expression in HepG2 cell 
line. The indicated miR-107 expression is the observed miR-107 expression divided by the 
level of miR-107 expression in basal HNF1α condition. Statistical analysis by Spearman test. 
 
Fig. 4. miRNAs deregulation associated to risk factors and oncogene mutation in HCC. (A) 
miR-126* was under-expressed in HCC related to alcohol abuse (Al+; FS n=7; VS n=6) vs 
others HCC (Al-; FS n=10, VS n=8). (B) miR-96 was over-expressed in Hepatitis B Virus 
infected HCC (HBV+; FS n=9; VS n=9) versus non infected HCC (HBV-: FS n=10; VS n=8). 
(C) miR-375 is down expressed in β-catenin mutated HCC (β-c Mut; FS n=7, VS n=8) versus 
non mutated (β-c Wt; FS n=21, VS n=14) HCC. For Normal Liver (NL) and Non Tumor Liver 
(NTL) distribution, see Fig. 2. (D) Correlation between miR-375 and three genes regulated by 
ß-catenin in hepatocellular tumors. FS=First Set of tumors, VS=Validation Set of tumors. 
 
Fig. 5. miRNAs expression is associated to different subgroups of hepatocellular tumors. 






Supplementary Fig.  1. Inhibition of HNF1α protein expression was shown 72 hours after 
transfection of HepG2 by 10 nM of a specific siRNA (see Patients and methods).  
 
Supplementary Fig. 2. PANK1 expression is not correlated with HNF1α expression when 
HNF1α expression was modulated by siRNA.    
 
 
Supplementary Fig. 3. miR-126* and miR-96 expression in non tumor liver (NTL). Non 
Cirrhotic NTL (NTL Non Cirr; n=7), Cirrhotic NTL (NTL Cirr; n=9), NTL non exposed to 
alcohol (NTL Alcohol-; n=11), NTL exposed to alcohol (NTL Alcohol+; n=5), NTL non infected 
by HBV (NTL HBV-; n=10), NTL infected by HBV (NTL HBV+; n=6).  
 
 
